Abstracts Archive - Page 1579 of 2607 - ACR Meeting Abstracts

Abstract Number: 2876 • 2017 ACR/ARHP Annual Meeting
Analysis of Autoantibody Reactivity to the Complete Human Peptidome By Phage Immunoprecipitation Sequencing Does Not Identify a Predominant Novel Autoantibody in Sjogren’s Syndrome
Tiezheng Yuan¹, Michelle Petri², Alan N. Baer³ and H. Benjamin Larman¹, ¹Pathology (Immunology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: An unbiased and comprehensive approach to the analysis of Sjögren’s syndrome (SS) antibody repertoires would provide important data on its pathogenesis. Phage ImmunoPrecipitation sequencing…
Abstract Number: 2877 • 2017 ACR/ARHP Annual Meeting
Premature Senescence of Naive CD4+ T-Cells in Primary Sjogren’s Syndrome
Patrizia Fasching¹, Johannes Fessler², Andrea Raicht³, Angelika Lackner², Josef Hermann², Rusmir Husic¹, Sabrina Hammerl⁴, Winfried Graninger², Wolfgang Schwinger³, Christian Dejaco¹ and Martin Stradner¹, ¹Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³Division of Pediatric Hemato-Oncology, Medical University of Graz, Graz, Austria, ⁴Medical University of Graz, Graz, Austria
Background/Purpose: Lymphopenia is a frequent finding in primary Sjögren’s syndrome (pSS) affecting mostly the CD4+ T-cell population. Here we examine possible underlying defects in thymic…
Abstract Number: 2878 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Atul A. Deodhar¹, Alice B Gottlieb², Wolf-Henning Boehncke³, Bin Dong⁴, Yuhua Wang⁴, Yanli Zhuang⁴, William Barchuk⁵, Xie L. Xu⁵ and Elizabeth Hsia⁴, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Department of Dermatology, New York Medical College, Valhalla, NY, ³Geneva University Hospital and University of Geneva, Geneva, Switzerland, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, San Diego, CA
Background/Purpose: Evaluate efficacy and safety of guselkumab (GUS) in patients (pts) with active psoriatic arthritis (PsA) over 56 weeks (wks). Methods: Pts w/active PsA (defined…
Abstract Number: 2879 • 2017 ACR/ARHP Annual Meeting
Switching from Adalimumab to Chs-1420: A Randomized, Double-Blind Global Clinical Trial in Patients with Psoriasis and Psoriatic Arthritis
Jennifer Hodge, Hong Tang, Paula O'Connor and Barbara Finck, Coherus BioSciences, Inc., Redwood City, CA
Background/Purpose: CHS-1420 is a proposed biosimilar to adalimumab. A phase 3, randomized, double-blind, multicenter study evaluated the equivalence of CHS-1420 to adalimumab in patients with…
Abstract Number: 2880 • 2017 ACR/ARHP Annual Meeting
Clinical Evolution of Patients with Inflammatory Back Pain: A Population-Based Longitudinal Cohort Study
Runsheng Wang¹, Cynthia S. Crowson², Kerry Wright³ and Michael Ward⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴NIH/NIAMS, Bethesda, MD
Title: Clinical Evolution of Patients with Inflammatory Back Pain: a Population-Based Longitudinal Cohort Study Authors: Runsheng Wang1, Cynthia Crowson2, Kerry Wright2, Michael Ward31. Columbia University…
Abstract Number: 2881 • 2017 ACR/ARHP Annual Meeting
Pre-Existing Psoriasis Is Predictive for Clinical Relapse after Drug-Free Remission Induced By Therapy with Golimumab in Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Thomas Renson³, Roos Colman⁴, Dirk Elewaut⁵ and Filip van Den Bosch⁶, ¹Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, ³Rheumatology, Ghent University Hospital, GENT, Belgium, ⁴Department of Public Health, Ghent University, Ghent, Belgium, Biostatistics Unit,Ghent University, Ghent, Belgium, Ghent, Belgium, ⁵VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, ⁶Rheumatology, Ghent University Hospital, Gent, Belgium
Background/Purpose: The use of new treatment strategies in early stages of spondyloarthritis (SpA) makes it possible to achieve remission or low disease activity in more…
Abstract Number: 2882 • 2017 ACR/ARHP Annual Meeting
IgG Galactosylation Status Combined with MYOM2 SNP Precisely Predicts Anti-TNF Response in Ankylosing Spondylitis
Jing Liu¹, Shifang Ren², Zhenmin Niu¹, Qi Zhu³, Wei Wan⁴, Jing Han², Yanyun Ma⁵, Weilin Pu⁶, Yuan Li¹, Xia Xu⁴, Yi Wang⁵, Dongbao Zhao⁴, Hui Zhang⁷, Feng Qian⁵, Xiaodong Zhou⁸, John D. Reveille⁹, Li Jin^1,10, Dong-yi He³, Hejian Zou^11,12, Jianxin Gu² and Jiucun Wang^10,12,13, ¹State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ²Department of Biochemistry and Molecular Biology, Key Laboratory of Glycoconjugate Research Ministry of Public Health, School of Basic Medical Sciences, Fudan University, Shanghai, China, ³Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital, Shanghai, China, ⁴Department of Rheumatology and Immunology, Changhai Hospital, Shanghai, China, ⁵Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China, ⁶State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences,, State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai, China, Shanghai, China, ⁷School of Life Sciences, State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ⁸Internal Medicine-Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹University of Texas McGovern Medical School, Houston, TX, ¹⁰Fudan-Taizhou Institute of Health Sciences, Taizhou, China, ¹¹Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, ¹²Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China, ¹³State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, CN
Background/Purpose: Ankylosing spondylitis (AS) is an immune-mediated inflammatory disorder of spine and sacroiliac joints, which could lead to bony fusion of vertebral joints. TNF-blockers have…
Abstract Number: 2883 • 2017 ACR/ARHP Annual Meeting
Prevalence of Cardiovascular Risk Factors and Subclinical Cardovacular Disease in Psoriatic Arthritis
María Paz Martínez-Vidal¹, Cristina Fernández-Carballido², Mariano Andres³, Vega Jovaní⁴, Carlos Santos⁵, Maria Nieves Martínez Alberola⁶, Francisca Sivera⁷ and Raquel Martin-domenech⁶, ¹Rheumatology, Hospital general universitario de Alicante, Alicante, Spain, ²Hospital General Universitario de Elda, Elda, Spain, ³RHEUMATOLOGY, Hospital general universitario de Alicante, Alicante, Spain, ⁴Reumatología, Hospital general universitario de Alicante, Alicante, Spain, ⁵Rheumatology, Hospital de Alcoy, Alcoy, Spain, ⁶Rheumatology, Hospital General Universitario de Elda, Elda, Spain, ⁷Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain
Background/Purpose: SCORE tables underestimate the Cardiovascular Risk (CVR) for patients with Rheumatoid Arthritis (RA) and EULAR recommends multiplying by 1.5 the CVR obtained from them…
Abstract Number: 2884 • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Systemic sclerosis (SSc) is characterized in part by chronic activation of the innate immune system with fibrosis. Anabasum is a non-immunosuppressive, synthetic, orally administered…
Abstract Number: 2885 • 2017 ACR/ARHP Annual Meeting
Tadalafil Reduces Skin Fibrosis and Profibrotic Genes Expression in Patients with Systemic Sclerosis
Sakir Ahmed, Mohit Kumar Rai, Durga Prasanna Misra and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Currently, drugs that modify skin fibrosis in Systemic Sclerosis (SSc) have efficacy in certain subgroups of patients only. Phosphodiesterase-5 inhibitors (PDE5i) are known to…
Abstract Number: 2886 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Long-Time Intensified Rituximab Treatment in Patients with Systemic Sclerosis
Hans-Peter Brezinschek¹, Sonja Kielhauser², Winfried Graninger³ and Florentine Moazedi-Fürst², ¹Internal Medicine/Division of Rheumatoloy and Immunology, Rheumatology and Immunology, Medical University Graz, Austria, Graz, Austria, ²Rheumatology and Immunology, Medical University Graz, Austria, Graz, Austria, ³Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Background/Purpose: Rituximab (RTX), a monoclonal B cell depleting antibody, is one of the few new drugs that has been shown to have beneficial effects on…
Abstract Number: 2887 • 2017 ACR/ARHP Annual Meeting
Long-Term Follow-up Report on Japanese Patients with Severe Systemic Sclerosis after Autologous Hematopoietic Stem Cell Transplantation
Hiroyuki Nakamura¹, Shinsuke Yasuda¹, Atsushi Noguchi², Toshio Odani³, Yuichiro Fujieda¹, Masaru Kato¹, Kenji Oku¹, Junichi Sugita⁴, Toshiyuki Bohgaki¹, Tomoyuki Endo⁴, Takanori Teshima⁴ and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Third Department of Internal Medicine, Obihiro-Kosei General Hospital, Hokkaido, Japan, ⁴Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Systemic sclerosis (SSc) comprises diverse clinical phenotypes with variable disease courses. Some SSc patients take miserable and fatal clinical course due to rapid progressive…
Abstract Number: 2888 • 2017 ACR/ARHP Annual Meeting
Corticosteroid-Sparing Benefit of Intravenous Immunoglobulins in Systemic Sclerosis-Associated Inflammatory Myopathy: A Retrospective Study of 54 Patients
Benjamin Chaigne¹, Simao Rodeia², Nouria Benmostefa^2,3,4, Alice Bérezné⁵, Pascal Cohen⁶, Alexis Regent⁷, Benjamin Terrier⁶, Nathalie Costedoat-Chalumeau⁸, Loïc Guillevin⁹, Claire Le Jeunne⁶ and Luc Mouthon¹⁰, ¹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares d’Ile de France, hôpital Cochin, DHU Authors, Assistance Publique-Hôpitaux de Paris, Paris, France, ²Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares d’Ile de France, DHU Authors, hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Service de Médecine Interne CHU de Sétif, Algérie, Sétif, Algeria, ⁴Faculté de Médecine, Université de Sétif 1, Sétif, Algeria, ⁵Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ⁶Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁸Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁹Internal medicine, Cochin University Hospital, paris, France, ¹⁰Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: Little is known about systemic sclerosis (SSc)-associated myopathy (SScAM) treatment. Intravenous immunoglobulin (IVIg) are used off-label in SScAM. Herein we aimed to evaluate the…
Abstract Number: 2889 • 2017 ACR/ARHP Annual Meeting
Aminaphtone Ameliorates Clinical Symptoms and Increases Skin Blood Perfusion in Patients with Both Primary and Secondary Raynaud Phenomenon: A Six-Month Open Study
Alberto Sulli¹, Maurizio Cutolo², Carmen Pizzorni², Sabrina Paolino², Elisa Alessandri², Emanuele Gotelli² and Barbara Ruaro², ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Current treatments for Raynaud's phenomenon (RP) have limited efficacy, which was mainly demonstrated by physician/patient reported outcomes. Aminaphtone is a vasoactive drug recently suggested…
Abstract Number: 2890 • 2017 ACR/ARHP Annual Meeting
Performance of Machine Learning Methods Using Electronic Medical Records to Predict Varicella Zoster Virus Infection
Milena Gianfrancesco¹, Gabriela Schmajuk², Sara Murray³, Dana Ludwig³, Awni Hannun⁴, Anand Avati⁴, Suzanne Tamang⁵ and Jinoos Yazdany⁶, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Computer Science, Stanford University, Palo Alto, CA, ⁵Stanford Center for Population Health Science, Stanford University, Palo Alto, CA, ⁶Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Varicella zoster virus infections (VZV) can be associated with significant morbidity in immunosuppressed hosts. However, methods do not exist to systematically identify which patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].